1083 related articles for article (PubMed ID: 9135694)
1. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
2. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
3. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
4. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
5. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
6. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
[TBL] [Abstract][Full Text] [Related]
7. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
Bartsch G; Rittmaster RS; Klocker H
Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
[TBL] [Abstract][Full Text] [Related]
9. Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride.
Golchin-Rad K; Mogheiseh A; Nazifi S; Ahrari Khafi MS; Derakhshandeh N; Abbaszadeh-Hasiri M
Top Companion Anim Med; 2020 Mar; 38():100405. PubMed ID: 32115076
[TBL] [Abstract][Full Text] [Related]
10. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
[TBL] [Abstract][Full Text] [Related]
11. Androgen metabolism in men receiving finasteride before prostatectomy.
Norman RW; Coakes KE; Wright AS; Rittmaster RS
J Urol; 1993 Nov; 150(5 Pt 2):1736-9. PubMed ID: 7692110
[TBL] [Abstract][Full Text] [Related]
12. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
[TBL] [Abstract][Full Text] [Related]
13. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
George FW
Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
[TBL] [Abstract][Full Text] [Related]
14. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression.
Cohen SM; Werrmann JG; Rasmusson GH; Tanaka WK; Malatesta PF; Prahalada S; Jacobs JG; Harris G; Nett TM
Prostate; 1995 Feb; 26(2):55-71. PubMed ID: 7531846
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone.
Dadras SS; Cai X; Abasolo I; Wang Z
Gene Expr; 2001; 9(4-5):183-94. PubMed ID: 11444528
[TBL] [Abstract][Full Text] [Related]
17. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
18. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
[TBL] [Abstract][Full Text] [Related]
19. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride.
Geller J; Sionit L
J Cell Biochem Suppl; 1992; 16H():109-12. PubMed ID: 1283893
[TBL] [Abstract][Full Text] [Related]
20. Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia.
Park BK; Kim CW; Kwon JE; Negi M; Koo YT; Lee SH; Baek DH; Noh YH; Kang SC
Pharm Biol; 2019 Dec; 57(1):90-98. PubMed ID: 30724641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
